$20.87
1.76% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

MediWound Ltd. Stock price

$20.87
+3.22 18.24% 1M
+4.09 24.37% 6M
+3.07 17.25% YTD
+3.54 20.43% 1Y
+8.17 64.27% 3Y
+7.03 50.78% 5Y
-16.51 44.17% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.36 1.76%
ISIN
IL0011316309
Symbol
MDWD
Sector
Industry

Key metrics

Market capitalization $225.56m
Enterprise Value $189.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.36
P/S ratio (TTM) P/S ratio 11.16
P/B ratio (TTM) P/B ratio 7.23
Revenue growth (TTM) Revenue growth 8.22%
Revenue (TTM) Revenue $20.22m
EBIT (operating result TTM) EBIT $-19.38m
Free Cash Flow (TTM) Free Cash Flow $-17.40m
Cash position $43.16m
EPS (TTM) EPS $-3.07
P/E forward negative
P/S forward 9.41
EV/Sales forward 7.90
Short interest 11.09%
Show more

Is MediWound Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

MediWound Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a MediWound Ltd. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a MediWound Ltd. forecast:

Buy
100%

Financial data from MediWound Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
20 20
8% 8%
100%
- Direct Costs 18 18
16% 16%
87%
2.63 2.63
27% 27%
13%
- Selling and Administrative Expenses 12 12
13% 13%
58%
- Research and Development Expense 8.88 8.88
19% 19%
44%
-18 -18
26% 26%
-89%
- Depreciation and Amortization 1.48 1.48
14% 14%
7%
EBIT (Operating Income) EBIT -19 -19
25% 25%
-96%
Net Profit -30 -30
350% 350%
-149%

In millions USD.

Don't miss a Thing! We will send you all news about MediWound Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MediWound Ltd. Stock News

Positive
Seeking Alpha
5 days ago
I rate MediWound a buy due to strong revenue growth, a robust pipeline, and significant undervaluation with massive upside potential. NexoBrid's commercial success and orphan drug status drive revenue growth, while EscharEx's promising phase 3 trial could unlock a huge chronic wound market. The company's strong balance sheet, with ample cash and minimal debt, provides a solid runway for R&D and...
Neutral
GlobeNewsWire
8 days ago
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL® Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL®
Neutral
GlobeNewsWire
16 days ago
Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time Conference call and webcast scheduled for Wednesday, May 21, 2025, at 8:30 a.m. Eastern Time
More MediWound Ltd. News

Company Profile

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Head office Israel
CEO Ofer Gonen
Employees 111
Founded 2000
Website www.mediwound.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today